STOCK TITAN
  1. Home
  2. News
  3. ABUS

Arbutus Biopharma Corporation - ABUS STOCK NEWS

Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.

Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.

Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.

Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.

Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.

News

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Rhea-AI Summary
Arbutus Biopharma (Nasdaq: ABUS) will report its first quarter 2024 financial results and provide a corporate update on May 2, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences earnings
-
News

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Rhea-AI Summary
Arbutus Biopharma (ABUS) issues a statement on the claim construction ruling by the U.S. District Court regarding the lawsuit against Moderna, Inc. The Court's Opinion addresses key patent claims related to Moderna's COVID-19 vaccine, MRNA-1273.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
News

Arbutus to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced participation in investor conferences to discuss its progress in developing a functional cure for chronic hepatitis B virus infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
News

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports strong financial position with cash and investments of $132M, plans for key clinical data in 2024, and ongoing Phase 2a trials with imdusiran and AB-101.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
earnings
-
News

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced the schedule for its Q4 and year-end 2023 financial results and corporate update, set for February 29, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection leveraging its virology expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced its 2024 business outlook, including clinical development milestones for its HBV pipeline and a financial update. The company's strong balance sheet and anticipated clinical trial readouts position it well towards achieving its mission of developing a functional cure for patients with chronic hepatitis B virus (cHBV). The Phase 2a program for imdusiran, the company's RNAi therapeutic, reinforces the potential role of imdusiran as a cornerstone in a treatment regimen to functionally cure patients with cHBV. Additionally, AB-101, the company's oral PD-L1 inhibitor, continues to progress, with preliminary data expected from the ongoing Phase 1a/1b clinical trial. Arbutus also provided an update on the claim construction hearing for Moderna LNP litigation and its strong financial position with a cash runway into Q1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
News

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) and Barinthus Biotherapeutics plc (BRNS) announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, presenting preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran, with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy. The data showed a meaningful reduction of HBsAg levels, robust reductions of HBsAg during the imdusiran treatment period, and preliminary immunology data suggesting HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
clinical trial
-
News

Arbutus to Present at Jefferies London Healthcare Conference

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced their participation in the Jefferies London Healthcare Conference on November 15, 2023, presenting their efforts in developing a cure for chronic hepatitis B virus (cHBV) infection. The live webcast of the presentation can be accessed at https://investor.arbutusbio.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences
-
News

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third-quarter 2023 financial results and provided a corporate update. They will be presenting preliminary data at AASLD from the first group of patients in its Phase 2a clinical trial evaluating imdusiran, nucleos(t)ide analogue (NA) therapy, and VTP-300, an HBV antigen-specific immunotherapy. Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, their oral PD-L1 checkpoint inhibitor. They are reducing their workforce by 24% as a result of recent pipeline optimization. The cash runway has been extended into the first quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
News

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that William Collier will retire from his position as President and CEO, with Michael J. McElhaugh, Co-founder and COO, stepping in as Interim CEO effective January 1, 2024. The company expressed gratitude for Collier's leadership and confidence in McElhaugh's ability to advance Arbutus' pipeline and shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none

FAQ

What is the current stock price of Arbutus Biopharma Corporation (ABUS)?

The current stock price of Arbutus Biopharma Corporation (ABUS) is $3.21 as of December 20, 2024.

What is the market cap of Arbutus Biopharma Corporation (ABUS)?

The market cap of Arbutus Biopharma Corporation (ABUS) is approximately 610.2M.

What is Arbutus Biopharma's primary focus?

Arbutus Biopharma focuses on discovering, developing, and commercializing therapeutics to cure patients suffering from chronic hepatitis B virus (cHBV) infection.

What is imdusiran (AB-729)?

Imdusiran (AB-729) is an RNA interference (RNAi) therapeutic designed to target and reduce HBV proteins, aiding in the reduction of hepatitis B surface antigen and enabling the host's immune system to respond to the virus.

What are the key recent achievements of Arbutus Biopharma?

Recent achievements include promising clinical trial results for imdusiran, showing sustained HBsAg loss and potential functional cure in some patients, as well as ongoing patent litigation to protect their LNP technology used in mRNA COVID-19 vaccines.

What is the status of Arbutus' financial condition?

Arbutus maintains a strong financial position with cash, cash equivalents, and investments providing a cash runway into the first quarter of 2026.

What technologies does Arbutus leverage for its treatments?

Arbutus leverages RNA interference (RNAi) therapeutics and lipid nanoparticle (LNP) technology in developing innovative treatments for HBV and other diseases.

What are the current projects Arbutus Biopharma is working on?

Arbutus is conducting multiple Phase 2a clinical trials for imdusiran in combination with other therapeutics and is evaluating AB-101, an oral PD-L1 inhibitor, in a Phase 1a/1b trial.

Has Arbutus formed any strategic partnerships?

Yes, Arbutus has formed strategic collaborations and partnerships to advance its therapeutic goals and continues to explore new opportunities to enhance its pipeline and clinical programs.

What is the significance of Arbutus' patent litigation?

Arbutus is involved in ongoing lawsuits against Moderna and Pfizer/BioNTech to seek fair compensation for the use of its patented LNP technology in COVID-19 vaccines.

How successful have Arbutus' clinical trials been?

Arbutus' clinical trials have shown promising results, with imdusiran demonstrating significant reductions in HBsAg levels and potential functional cures in some chronic hepatitis B patients.

Where can more information about Arbutus Biopharma be found?

More information about Arbutus Biopharma can be found on their official website at www.arbutusbio.com.

Stock ABUS logo
Arbutus Biopharma Corporation

Nasdaq:ABUS

ABUS Rankings

#2930 Ranked by Market Cap
N/A Ranked by Dividends

ABUS Stock Data

610.16M
147.20M
22.22%
53.86%
3.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WARMINSTER